

# Diabetes Care

THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION

September 2018 Volume 41, Number 9

## In This Issue

1833 In This Issue of *Diabetes Care*

## Perspectives in Care

1835 Considerations in Epidemiologic Definitions of Undiagnosed Diabetes  
*L.S. Geiss, K.M. Bullard, R. Brinks, and E.W. Gregg*

## Commentaries

1839 Increasing Hospitalizations for DKA: A Need for Prevention Programs  
*P. Vellanki and G.E. Umpierrez*

1842 Is Mini-Dose Glucagon the Answer to Preventing Exercise-Related Dysglycemia?  
*J.R. Castle*

## Clinical Care/Education/Nutrition/Psychosocial Research

1844 Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data  
*J.M. Dennis, W.E. Henley, M.N. Weedon, M. Lonergan, L.R. Rodgers, A.G. Jones, W.T. Hamilton, N. Sattar, S. Janmohamed, R.R. Holman, E.R. Pearson, B.M. Shields, and A.T. Hattersley, on behalf of the MASTERMIND Consortium*

1854 High Diabetes Distress Among Ethnic Minorities Is Not Explained by Metabolic, Cardiovascular, or Lifestyle Factors: Findings From the Dutch Diabetes Pearl Cohort  
*B. Özcan, F. Rutters, F.J. Snoek, M. Roosendaal, E.J. Sijbrands, P.J.M. Elders, F. Holleman, H. Pijl, C.J. Tack, E.J. Abink, H.W. de Valk, B.H.R. Wolffenbuttel, C.D.A. Stehouwer, N.C. Schaper, J.M. Dekker, and M.T. Schram, on behalf of the Diabetes Pearl from the Parelstoer Initiative*

1862 T1-REDEEM: A Randomized Controlled Trial to Reduce Diabetes Distress Among Adults With Type 1 Diabetes  
*L. Fisher, D. Hessler, W.H. Polonsky, U. Masharani, S. Guzman, V. Bowyer, L. Strycker, A. Ahmann, M. Basina, I. Blumer, C. Chloe, S. Kim, A.L. Peters, M. Shumway, K. Weihs, and P. Wu*

## Epidemiology/Health Services Research

→ 1870 Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study  
*V.W. Zhong, J. Juhaeri, and E.J. Mayer-Davis*

1878 Adiposity-Mortality Relationships in Type 2 Diabetes, Coronary Heart Disease, and Cancer Subgroups in the UK Biobank, and Their Modification by Smoking  
*D.A. Jenkins, J. Bowden, H.A. Robinson, N. Sattar, R.J.F. Loos, M.K. Rutter, and M. Sperrin*

→ 1887 A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk  
*M.J. Redondo, S. Geyer, A.K. Steck, S. Sharp, J.M. Wentworth, M.N. Weedon, P. Antinozzi, J. Sosenko, M. Atkinson, A. Pugliese, R.A. Oram, and the Type 1 Diabetes TrialNet Study Group*


1895 Effects of High Blood Pressure on Cardiovascular Disease Events Among Chinese Adults With Different Glucose Metabolism  
*J. Tian, C.-S. Sheng, W. Sun, X. Song, H. Wang, Q. Li, W. Li, and W. Wang*


1901 Biochemical Markers of Bone Turnover and Risk of Incident Diabetes in Older Women: The Cardiovascular Health Study  
*D. Massera, M.L. Biggs, M.D. Walker, K.J. Mukamal, J.H. Ix, L. Djousse, R.J. Valderrábano, D.S. Siscovick, R.P. Tracy, X. Xue, and J.R. Kizer*

## Emerging Therapies: Drugs and Regimens

1909 Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes  
*M.R. Rickels, S.N. DuBose, E. Toschi, R.W. Beck, A.S. Verdejo, H. Wolpert, M.J. Cummins, B. Newschwanger, and M.C. Riddell, for the T1D Exchange Mini-Dose Glucagon Exercise Study Group*

1917 Low-Dose Anti-Thymocyte Globulin (ATG) Preserves  $\beta$ -Cell Function and Improves HbA<sub>1c</sub> in New-Onset Type 1 Diabetes  
*M.J. Haller, D.A. Schatz, J.S. Skyler, J.P. Krischer, B.N. Bundy, J.L. Miller, M.A. Atkinson, D.J. Becker, D. Baidal, L.A. DiMeglio, S.E. Gitelman, R. Goland, P.A. Gottlieb, K.C. Herold, J.B. Marks, A. Moran, H. Rodriguez, W. Russell, D.M. Wilson, C.J. Greenbaum, and the Type 1 Diabetes TrialNet ATG-GCSF Study Group*

1926  A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin  
*I. Lingvay, C.V. Desouza, K.S. Lalic, L. Rose, T. Hansen, J. Zacho, and T.R. Pieber*

1938  Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial  
*C. Mathieu, P. Dandona, P. Gillard, P. Senior, C. Hasslacher, E. Araki, M. Lind, S.C. Bain, S. Jabbour, N. Arya, L. Hansen, F. Thorén, and A.M. Langkilde, on behalf of the DEPICT-2 Investigators*

## Pathophysiology/Complications

1947 Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes  
*A. Heinzel, M. Kammer, G. Mayer, R. Reindl-Schwaighofer, K. Hu, P. Perco, S. Eder, L. Rosivall, P.B. Mark, W. Ju, M. Kretzler, P. Gilmour, J.M. Wilson, K.L. Duffin, M. Abdalla, M.I. McCarthy, G. Heinze, H.L. Heerspink, A. Wiecek, M.F. Gomez, and R. Oberbauer, for the BEAT-DKD Consortium*

1955 Risk-Factor Trajectories Preceding Diabetic Polyneuropathy: ADDITION-Denmark  
*S.T. Andersen, D.R. Witte, H. Andersen, L. Bjerg, N.H. Bruun, M.E. Jørgensen, N.B. Finnerup, T. Lauritzen, T.S. Jensen, H. Tankis, and M. Charles*

→ 1963 Renal and Cardiovascular Risk According to Tertiles of Urinary Albumin-to-Creatinine Ratio: The Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AddIT)  
*M.L. Marcovecchio, S.T. Chiesa, J. Armitage, D. Daneman, K.C. Donaghue, T.W. Jones, F.H. Mahmud, S.M. Marshall, H.A.W. Neil, R.N. Dalton, J. Deanfield, and D.B. Dunger, on behalf of the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AddIT) Study Group*

Keep up with the latest information for *Diabetes Care* and other ADA titles via Facebook (/ADAJournals) and Twitter (@ADA\_Journals).

All articles in *Diabetes Care* are available online at [diabetes.org/diabetescare](http://diabetes.org/diabetescare). Cover articles (➡) and select content are available free of charge. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

ADA's *Diabetes Core Update* podcasts are available at [diabetesjournals.org](http://diabetesjournals.org) and through iTunes.

Icons shown below appear on the first page of an article if more information is available online.



Free Article



Video



Podcast





Supplementary Data



Companion Article

## Cardiovascular and Metabolic Risk

- 1970**  Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study  
*J.B. Buse, S.K. Garg, J. Rosenstock, T.S. Bailey, P. Banks, B.W. Bode, T. Danne, J.A. Kushner, W.S. Lane, P. Lapuerta, D.K. McGuire, A.L. Peters, J. Reed, S. Sawhney, and P. Strumph*
- 1981** HbA<sub>1c</sub> and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study  
*T. Danne, B. Cariou, P. Banks, M. Brandle, H. Brath, E. Franek, J.A. Kushner, P. Lapuerta, D.K. McGuire, A.L. Peters, S. Sawhney, and P. Strumph*
- 1991** The Impact of Glycated Hemoglobin (HbA<sub>1c</sub>) on Cardiovascular Disease Risk: A Mendelian Randomization Study Using UK Biobank  
*S.L. Au Yeung, S. Luo, and C.M. Schooling*
- 1998** Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults  
*T. Wang, J.-L. Hong, E.W. Gower, V. Pate, S. Garg, J.B. Buse, and T. Stürmer*
- 2010** Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register  
*S.H. Read, M. van Diepen, H.M. Colhoun, N. Halbesma, R.S. Lindsay, J.A. McKnight, D.A. McAllister, E.R. Pearson, J.R. Petrie, S. Philip, N. Sattar, M. Woodward, and S.H. Wild, on behalf of the Scottish Diabetes Research Network Epidemiology Group*
- 2019**  Poor Glycemic Control Is Associated With Increased Extracellular Volume Fraction in Diabetes  
*A. Al-Badri, Z. Hashmath, G.H. Oldland, R. Miller, K. Javaid, A.A. Syed, B. Ansari, S. Gaddam, W.R. Witschey, S.R. Akers, and J.A. Chirinos*

## Position Statement

- ➡ **2026** Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association  
*J.L. Chiang, D.M. Maahs, K.C. Garvey, K.K. Hood, L.M. Laffel, S.A. Weinzimer, J.I. Wolfsdorf, and D. Schatz*

## Standards of Care Updates

- 2045** Updates to the *Standards of Medical Care in Diabetes—2018*

## Errata

- 2048** Erratum. Intensive Versus Standard Blood Pressure Control in SPRINT-Eligible Participants of ACCORD-BP. *Diabetes Care* 2017;40:1733–1738  
*L.F. Buckley, D.L. Dixon, G.F. Wohlford IV, D.S. Wijesinghe, W.L. Baker, and B.W. Van Tassel*
- 2048** Erratum. Why Are We Failing to Address the Issue of Access to Insulin? A National and Global Perspective. *Diabetes Care* 2018;41:1125–1131  
*D. Beran, I.B. Hirsch, and J.S. Yudkin*

## Issues and Events

- 2049** Issues and Events

## e-Letters – Observations

- e130** Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database  
*M. Arai, J. Shirakawa, H. Konishi, N. Sagawa, and Y. Terauchi*
- e133** Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide  
*J.S. Knudsen, R.W. Thomsen, A. Pottegård, F.K. Knop, and H.T. Sørensen*

## e-Letters – Comments and Responses

- e136** Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. *Diabetes Care* 2018;41:187–192  
*B.L. Pearlman, A. Hinds, and A.-E.Z. Dakaud*
- e137** Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. *Diabetes Care* 2018;41:187–192  
*F. Bril and K. Cusi*